These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 19553086

  • 1. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
    Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, Sudo Y, Asukai N, Nakamura H, Usui C, Kawabata T, Hirata T, Sawa Y.
    Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.
    McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, Hasan SM.
    Br J Psychiatry; 2006 Nov; 189():433-40. PubMed ID: 17077434
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
    Hatta K, Takebayashi H, Sudo Y, Katayama S, Kasuya M, Shirai Y, Morikawa F, Nakase R, Nakamura M, Ito S, Kuga H, Nakamura M, Ohnuma T, Usui C, Nakamura H, Hirata T, Sawa Y, JAST study group.
    Psychiatry Res; 2013 Dec 15; 210(2):396-401. PubMed ID: 23919898
    [Abstract] [Full Text] [Related]

  • 11. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
    Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC.
    J Child Adolesc Psychopharmacol; 2008 Aug 15; 18(4):317-26. PubMed ID: 18759641
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
    Hatta K, Otachi T, Sudo Y, Hayakawa T, Ashizawa Y, Takebayashi H, Hayashi N, Hamakawa H, Ito S, Nakase R, Usui C, Nakamura H, Hirata T, Sawa Y, JAST Study Group.
    Schizophr Res; 2011 May 15; 128(1-3):127-35. PubMed ID: 21420283
    [Abstract] [Full Text] [Related]

  • 14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec 15; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 15. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
    Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M.
    J Child Adolesc Psychopharmacol; 2016 Jun 15; 26(5):458-70. PubMed ID: 27093218
    [Abstract] [Full Text] [Related]

  • 16. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L, Czobor P, Bitter I.
    Schizophr Res; 2014 Jan 15; 152(1):246-54. PubMed ID: 24275583
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
    Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS, EUFEST study group.
    Schizophr Res; 2009 Dec 15; 115(2-3):97-103. PubMed ID: 19819114
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Soares-Weiser K, Béchard-Evans L, Lawson AH, Davis J, Ascher-Svanum H.
    Eur Neuropsychopharmacol; 2013 Feb 15; 23(2):118-25. PubMed ID: 22633617
    [Abstract] [Full Text] [Related]

  • 20. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I, Ravanić D, Popović V, Vladejić S, Stanojević A, Stojanović M.
    Psychiatr Danub; 2011 Dec 15; 23(4):384-8. PubMed ID: 22075740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.